Last Updated: 08 Nov 2024
Executive Summary
Absci Corp (ABSI) is a clinical-stage biotechnology company focused on developing and commercializing novel antibody therapeutics. The company's proprietary technology platform, AbsciOS, enables the rapid and efficient discovery and optimization of antibodies for a wide range of therapeutic applications.
Company Overview
Founded in 2013 and headquartered in Vancouver, Washington
Led by CEO Sean McClain, a seasoned biotech executive
Focuses on developing antibody therapeutics for oncology, immunology, and infectious diseases
Utilizes machine learning and automation to accelerate drug discovery and development
Fundamental Analysis
Revenue: TTM revenue of $3.25 million, down 0.623% YoY
Earnings: Diluted EPS of -$0.93 TTM
Profitability: Gross profit margin of -122.78% TTM, operating margin of -21.04% TTM
Valuation: Market capitalization of $457.63 million, price-to-sales ratio of 140.81 TTM, price-to-book ratio of 2.066
Technical Analysis
Trend: Stock price is currently trading in a downtrend, below its 50-day and 200-day moving averages
Support and Resistance: Key support levels at $3.50 and $2.50, resistance levels at $4.50 and $5.25
Momentum: Relative Strength Index (RSI) is below 50, indicating bearish momentum
Short Term Outlook
The stock is facing technical resistance at $4.50 and may struggle to break above this level in the near term.
Analysts have a consensus Buy rating, with an average target price of $8.29, indicating potential upside.
However, the company's weak financial performance and downward revenue trend may weigh on the stock price in the short term.
Long Term Outlook
Absci Corp's proprietary technology platform has the potential to revolutionize drug discovery and development.
The company has a strong pipeline of promising antibody candidates in various stages of clinical development.
If successful, Absci Corp could become a major player in the biotechnology industry.
Analyst Recommendations
Strong Buy: 0
Buy: 6
Hold: 1
Sell: 0
Strong Sell: 0
Conclusion
Absci Corp is a promising biotechnology company with a disruptive technology platform. While the company faces near-term challenges, its long-term potential is significant. Investors should consider the company's weak financial performance and technical resistance before making investment decisions.
